By Suherman Candra Maholtra 
The persistent threat of emerging infectious diseases has necessitated a paradigm shift in how the global scientific community approaches vaccine development and validation. In a significant breakthrough published in the journal eBioMedicine, researchers from the University of Tokyo have provided comprehensive evidence supporting the use of the LC16m8 vaccine—a third-generation attenuated smallpox vaccine—as a potent defense against the monkeypox virus (MPXV). Through a rigorous cross-species study involving three strains of mice, non-human primates, and human clinical specimens, the team demonstrated that LC16m8 not only induces robust immunity but also maintains a high safety profile, even against more aggressive modern variants of the virus.
The study, led by Associate Professor Kouji Kobiyama and Professor Ken J. Ishii of the Institute of Medical Science at the University of Tokyo, arrives at a critical juncture. As mpox continues to transition from a neglected endemic disease in Central and West Africa to a global health security concern, the demand for scalable and broadly protective vaccines has never been higher. The research, made available online in April 2025 and appearing in the May 2025 print edition of eBioMedicine, offers a scientific blueprint for evaluating vaccine efficacy across diverse biological models.
The Evolution of the Mpox Threat: From Endemic to Global Emergency
To understand the significance of the LC16m8 study, one must look at the epidemiological trajectory of the monkeypox virus. First identified in laboratory monkeys in 1958 and in humans in 1970 in the Democratic Republic of the Congo (DRC), MPXV remained largely localized for decades. However, the cessation of routine smallpox vaccination in the late 1970s and early 1980s left a growing portion of the global population with no cross-protective immunity against orthopoxviruses.
The situation escalated dramatically in 2022 when a global outbreak, primarily driven by Clade IIb of the virus, spread through sexual networks and close contact across non-endemic countries. This prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC). While that specific emergency was later downgraded, the emergence of Clade Ib—a more virulent and transmissible variant—in 2024 and 2025 has renewed fears of a deadlier pandemic wave. Unlike previous strains, Clade Ib has shown an increased ability to spread through household contacts and has been associated with higher mortality rates in children and immunocompromised individuals.
In this context, the LC16m8 vaccine represents a vital asset. Originally developed in Japan by the Chiba Serum Institute (now KM Biologics) as a safer alternative to the traditional smallpox vaccines used during the eradication era, LC16m8 was licensed for smallpox in 1975. In 2022, Japanese regulatory authorities expanded its indication to include mpox prevention, but global health bodies required more granular data on its performance against the latest viral lineages.
Methodology: A Multi-Tiered Cross-Species Approach
The University of Tokyo study was designed to bridge the gap between laboratory findings and real-world clinical application. By utilizing a "cross-species" approach, the researchers aimed to observe how the vaccine interacts with different immune systems, providing a more holistic view of its potential.
Mouse Models and Protective Efficacy
The team utilized three distinct mouse strains: BALB/c, C57BL/6J, and CAST/EiJ. The inclusion of CAST/EiJ mice was particularly crucial; this strain is known to be highly susceptible to orthopoxvirus infections, serving as a rigorous "worst-case scenario" model for vaccine testing.
Following vaccination with LC16m8, the researchers observed a significant induction of humoral responses. Specifically, the vaccine promoted the formation of germinal center B cells and follicular helper T cells. These components are the biological engines of long-term immunity, responsible for producing high-affinity antibodies and ensuring the body "remembers" the pathogen years after the initial shot. When challenged with the virus, the vaccinated CAST/EiJ mice showed remarkably reduced viral loads in their lung tissues compared to the control group, indicating that the vaccine effectively prevents systemic spread.
Non-Human Primate Safety Analysis
Safety remains a paramount concern for attenuated live vaccines. To test this, high doses of LC16m8 were administered to cynomolgus monkeys. The researchers monitored the primates for clinical signs of distress, including fluctuations in body weight, temperature spikes, and hematological abnormalities. The results were encouraging: while the monkeys developed localized pox lesions at the site of injection—a standard sign of successful "take" for vaccinia-based vaccines—they exhibited no systemic illness or significant physiological changes. This confirmed that the attenuation of the LC16m8 strain is stable and safe even at high concentrations.
Human Immunogenicity and Variant Neutralization
The final phase of the study involved blood samples from healthy human volunteers who had received the LC16m8 vaccine. The researchers tested the ability of the volunteers’ antibodies to neutralize various strains of the mpox virus. The data revealed that LC16m8 generated neutralizing antibodies that were effective not just against the ancestral strains, but also against the newer, more infectious variants circulating globally. Importantly, no serious adverse events were reported among the human subjects during the follow-up period, reinforcing the vaccine’s safety profile for public use.
Chronology of Development and Regulatory Milestones
The path of LC16m8 from a domestic smallpox reserve to a global mpox solution has been marked by several key dates:
- 1975: LC16m8 is officially licensed in Japan as an attenuated smallpox vaccine, replacing more reactive first-generation vaccines.
- 1980: Smallpox is declared eradicated; routine vaccination ceases, but Japan maintains LC16m8 in its national stockpile.
- 2022 (August): Following the global mpox outbreak, Japan’s Ministry of Health, Labour and Welfare approves LC16m8 for the prevention of monkeypox.
- 2024: Amidst the rise of Clade Ib in Africa, Japan pledges to donate significant quantities of LC16m8 to the DRC and other affected nations.
- April 15, 2025: The University of Tokyo releases its comprehensive cross-species study online, providing the scientific validation needed for broader international adoption.
- May 1, 2025: The full study is published in eBioMedicine, offering a peer-reviewed foundation for global health policy.
Strategic Implications for Global Health and Africa
The findings of Dr. Kobiyama and his team have immediate practical implications, particularly for the African continent. Currently, the distribution of mpox vaccines has been hampered by supply chain issues, cost, and a lack of data regarding efficacy against local clades.
"Since our research validates the efficacy and safety of LC16m8, it could accelerate approval and deployment of this vaccine in regions and populations highly susceptible to mpox outbreaks, particularly in Africa," noted Dr. Kobiyama.
The vaccine’s ability to be produced at scale and its history of use in Japan make it a viable candidate for mass inoculation campaigns. Furthermore, because LC16m8 is a single-dose vaccine (unlike some competitors that require two doses), it is significantly easier to administer in resource-limited settings or in conflict zones where follow-up appointments are difficult to maintain.
Analysis: A Blueprint for Future Pandemic Preparedness
Beyond mpox, this study establishes a "blueprint" for how the scientific community should respond to emerging pathogens. The use of multiple animal models alongside human data allows for a "triangulation" of results that increases confidence in a vaccine’s performance. In an era where "Disease X"—the next unknown pandemic threat—is a constant shadow, having a validated methodology for rapidly testing and repurposing existing vaccine platforms is invaluable.
The study also highlights the importance of targeting germinal center B cells. By focusing on the underlying mechanisms of how a vaccine creates "memory" in the immune system, researchers can better predict which candidates will provide multi-year protection versus those that might require frequent boosters.
Addressing Remaining Challenges
While the results are overwhelmingly positive, the researchers and the broader medical community acknowledge that work remains. Future studies must focus on:
- Immunocompromised Populations: Because LC16m8 is a live attenuated vaccine, its safety in individuals with advanced HIV or other immune-suppressing conditions needs further specialized study, though it is already considered safer than traditional smallpox vaccines.
- Pediatric Efficacy: With Clade Ib disproportionately affecting children in certain regions, clinical trials focusing on younger demographics are a high priority.
- Surveillance Integration: Dr. Kobiyama emphasizes that vaccines are only one part of the solution. "Our work can shape and guide the development of a permanent global surveillance and response system," he concluded. This includes better diagnostic tools and real-time genomic sequencing to track how the virus evolves in response to vaccine pressure.
Conclusion
The University of Tokyo’s research into LC16m8 provides a definitive scientific endorsement of a vaccine that could change the course of the mpox epidemic. By proving its efficacy across species and against modern variants, the study moves the global health community closer to a reality where mpox is no longer a persistent threat but a manageable, and perhaps eventually eradicated, disease. As the world looks toward more resilient healthcare systems, the LC16m8 vaccine stands out as a testament to the power of repurposing proven science to meet the challenges of a new age.